Pharmathen unveils plans to develop a new innovation hub in Attika
The investment will leverage Pharmathen's experience in injectable prolonged-release products.
Pharmathen announced the creation of a new innovation hub in Attica that will be completed in 2025 with a budget of € 50 million.
The design and construction of the new Pharmathen unit is based on the strict specifications of the EMA (European Medicines Agency) and the FDA (American Medicines Agency). Pharmathen already has two modern production units in Pallini, Attica and in Sapes, Rodopi and is the largest private investment body in Research and Development in Greece and one of the largest in Europe.
The investment will leverage Pharmathen's experience in injectable prolonged-release products as well as ophthalmic technologies, enhancing the company's competitive edge in the international pharmaceutical market, and creating at least 150 new jobs.
For the above investment, the Greek Prime Minister Kyriakos Mitsotakis had a meeting recently at the Maximos Palace, with Charles Dallara, Chairman of the Board, Partners Group USA, Thomas Werner, President of the Supervisory BoD, Pharmathen and Mr. Dimitris Kadis, CEO of Pharmathen .
It is recalled that BC Partners, to which Pharmathen has belonged since 2015, sold the pharmaceutical company to the Partners Group in mid-2021, for an amount of € 1.6 billion.